Overview
DNA Communications helps life sciences brands navigate the regulatory, scientific, and commercial landscape in healthcare. It develops strategic, educational, and behavioral-change programs and supports products across their lifecycle, offering services such as brand strategy, corporate and medical communications, events, media training, and market access. It translates science into clear messages and uses insights to solve health education problems, producing content and campaigns tailored to specific audiences. Its networks (IPG DXTRA and The Weber Shandwick Collective) and integrated approach differentiate it, with a goal to help clients communicate effectively, build reputation, and improve health outcomes.
Work here?Claim your company
Simplify's Take
What believers are saying
- DNA expanded U.S. medical education work with Pfizer and NS Pharma in 2024.
- Niamh Mangan's April 2024 London appointment strengthens transatlantic health communications leadership.
- Women’s Health Center of Excellence demand boosts DNA's relevance in high-growth therapeutic areas.
What critics are saying
- Current Group integration under Mike Rosich concentrates leadership and can distract execution through 2026.
- Pharma clients Pfizer and NS Pharma demand flawless compliance, and one misstep can kill trust.
- WPP, Omnicom, and Publicis health units outspend DNA, squeezing pricing and talent retention.
What makes DNA Communications unique
- Current Group keeps DNA Communications distinct while pairing it with Current Global.
- The U.S. Medical Education Center extends DNA's scientific storytelling into healthcare education.
- DNA's 70-person North America bench spans writers, creatives, experiential, and social specialists.
Help us improve and share your feedback! Did you find this helpful?